(Q30168082)

9 June 2017

1 reference

title

From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents (English)

1 reference

9 June 2017

angiogenesis inhibitor

1 reference

Morin MJ

1

1 reference

PubMed ID

11426642

9 June 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

9 June 2017

1 reference

9 June 2017

19

1 reference

9 June 2017

6574-6583

1 reference

9 June 2017

56

1 reference

The biology of stem cell factor and its receptor C-kit

9 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Assessment of HER2 status in breast cancer: why, when and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Anticancer drug targets: growth factors and growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Signaling--2000 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

The molecular genetics of Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Protein kinase inhibitors: the tyrosine-specific protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Protein tyrosine kinase inhibitors as novel therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Epidermal-growth-factor-dependent activation of the src-family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Kinase inhibitors in cancer therapy: a look ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

Tyrosine kinase inhibitor research presses on despite halted clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

7 January 2021

Signaling inhibitors in the clinic: new agents and new challenges

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

7 January 2021

Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

7 January 2021

Antiangiogenesis drugs target specific cancers, mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

7 January 2021

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

7 January 2021

Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204102

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1204102

1 reference

PubMed ID

11426642

Dimensions Publication ID

9 June 2017

0 references

1 reference

PubMed ID

11426642